Skip to content

Beam Therapeutics BEAM Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$414.64M-$398.58M-$386.4M
$22.37M+1.6%$22.29M+1.7%$22.07M+1.0%$21.98M+2.0%$22.02M+5.9%
$86.61M-26.6%$94.24M-21.9%$104.01M-8.0%$110.83M+1.4%$118.06M+13.5%
-$369.73M-5.2%-$345.1M+0.6%-$338.18M-$344.82M-$351.38M
$14.11M+47.4%$14.95M+67.1%$14.18M+48.3%$10.75M-32.6%$9.57M-68.3%
-$144.52M-219%$113.38M+1,703%
$101.28M-78.8%$478.05M+6,080%$479.61M+1,162%$479.19M+552%$478.22M+164%
-$239.53M$11.51M
-$383.84M-6.3%-$360.05M-1.1%-$352.36M-$355.57M-$360.96M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Beam Therapeutics generate?
Beam Therapeutics (BEAM) generated -$369.7M in operating cash flow over the trailing twelve months.
What is Beam Therapeutics's free cash flow?
After $14.1M of capital expenditures, Beam Therapeutics's free cash flow was -$383.8M over the trailing twelve months, down 6.3% year over year.
Where does Beam Therapeutics's cash flow data come from?
Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.